Tawam Dania, Baladi Michael, Jungsuwadee Paiboon, Earl Grace, Han Jayoung
Fairleigh Dickinson University School of Pharmacy and Health Sciences.
Innov Pharm. 2021 Mar 9;12(1). doi: 10.24926/iip.v12i1.3439. eCollection 2021.
Proton pump inhibitors (PPIs) are among the most commonly used medications by patients due to its availability over the counter and frequent prescribing by physicians to treat and alleviate symptoms of gastroesophageal reflux disease. Recently, the FDA issued a warning with respect to the utilization of PPIs and risk of developing Clostridium difficile infections (CDI). The most commonly known medications to cause CDI are antibiotics. However, available studies suggest an association and increase in risk for CDI with PPI use as well.
The purpose of this research is to review and summarize data currently available on the association between PPIs and CDI.
To search for eligible studies, EBSCO engines were investigated using proton pump inhibitors or PPIs and Clostridium difficile or C. diff. as search terms. Meta analyses and systematic reviews published between 2000 and 2020 on adult patients were considered.
Eight meta-analyses and systematic reviews met the inclusion criteria. They included studies conducted in the US, Europe, Asia and Canada on inpatient and outpatient adults. The final result for all 8 studies showed a statistically significant association between PPIs and CDI ranging from mild to high risk.
Currently available data suggest a positive association between PPIs and CDI.
质子泵抑制剂（PPIs）是患者最常用的药物之一，因为其可在柜台购买，且医生经常开此类药物来治疗和缓解胃食管反流病的症状。最近，美国食品药品监督管理局（FDA）就质子泵抑制剂的使用及艰难梭菌感染（CDI）风险发布了一项警告。最广为人知的可导致CDI的药物是抗生素。然而，现有研究表明，使用质子泵抑制剂也与CDI存在关联并会增加其风险。
本研究的目的是回顾和总结目前有关质子泵抑制剂与CDI之间关联的可用数据。
为了搜索符合条件的研究，使用质子泵抑制剂或PPIs以及艰难梭菌或艰难梭菌作为搜索词，对EBSCO数据库进行了检索。纳入了2000年至2020年间发表的关于成年患者的荟萃分析和系统评价。
八项荟萃分析和系统评价符合纳入标准。它们包括在美国、欧洲、亚洲和加拿大针对住院和门诊成年患者开展的研究。所有八项研究的最终结果显示，质子泵抑制剂与CDI之间存在统计学上的显著关联，风险范围从轻度到高度。
现有数据表明质子泵抑制剂与CDI之间存在正相关。
